Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Mold Immune Reactivity IgE: Cladosporium herbarum : 2.4 Penicillium chrysogen : 4.1 Remaining panel: negative IgG: Broad elevation across multiple molds (including Cladosporium, Aspergillus, Setomelanomma, Curvularia ) Clinical Interpretation of Findings Indicated: Strong mold-specific immune sensitization Intermediate Intervention: Immune Modulation and Neuroregulation Oral immunotherapy (1 5 drops over 5 weeks) L-theanine 200 mg three times daily Clinical Response: Substantial reduction in anxiety Improved cognitive clarity Improved emotional stability Escalation of Binding Therapy Cholestyramine introduced Clinical Response (2 months): Resolution of fatigue Resolution of pain Improved GI symptoms Reduced food intolerance Final Intervention: Glutathione IV glutathione titrated from 1000 mg 3000 mg over 6 weeks Clinical Response: Resolution of insomnia Outcome Neuropsychiatric symptoms resolved Systemic symptoms improved Sleep normalized Discussion Objective improvement may precede symptom resolution Early reductions in C4a and TGF-1 suggest physiologic improvement before full clinical recovery
The attacks of pain generally occur together and may repeat in succession, taking place sporadically over the course of days, weeks, or months
The human clinical research on CJC-1295 and Ipamorelin, while generating interest, is limited in scale and scope compared to FDA-approved medications
Research has examined DSIP's interactions with corticotropin-releasing hormone (CRH) and ACTH pathways, with investigators studying how the peptide influences stress hormone cascades in both in vitro and animal model systems
US$ 29.72
US$ 27.37
US$ 26.55
US$ 21.90
US$ 28.54
